Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00792636 · ClinicalTrials.gov registry record · Phase 4
A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period
A Phase 4 study of Migraine Disorders, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 407
- Enrollment target
- 20
- Study locations
NCT00792636: Completed Phase 4 study of Migraine Disorders, sponsored by GlaxoSmithKline.
NCT00792636 is a Phase 4 study of Migraine Disorders that has completed, run by GlaxoSmithKline. The registered enrollment target is 407 participants, above the 296-participant average among 21 other Migraine Disorders trials with a reported enrollment target (38% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00792636, a Phase 4 study of Migraine Disorders, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 407 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to test the effect on blood pressure of sumatriptan and naproxen sodium combination tablets, tablets containing only sumatriptan, and tablets containing only naproxen sodium when these drugs are taken to treat migraine headaches that occur during a 6-month period.
Primary Outcome
The calculation of baseline and post-baseline mean blood pressure (BP) (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean
Conditions Studied
Interventions
- DRUG sumatriptan and naproxen sodium combination tablet
- DRUG sumatriptan tablet
- DRUG naproxen sodium tablet
Study Locations (20)
California
- GSK Investigational Site - Anaheim
- GSK Investigational Site - Anaheim
- GSK Investigational Site - Buena Park
- GSK Investigational Site - Garden Grove
- GSK Investigational Site - Newport Beach
- GSK Investigational Site - Santa Monica
- GSK Investigational Site - Westlake Village
Arizona
- GSK Investigational Site - Chandler
- GSK Investigational Site - Gilbert
- GSK Investigational Site - Litchfield Park
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Tempe
Florida
- GSK Investigational Site - Hialeah
- GSK Investigational Site - Jacksonville
- GSK Investigational Site - Miami
- GSK Investigational Site - Pembroke Pines
- GSK Investigational Site - St. Petersburg
Arkansas
- GSK Investigational Site - Little Rock
Colorado
- GSK Investigational Site - Colorado Springs
Connecticut
- GSK Investigational Site - Avon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-11 |
| Phase | Phase 4 |
What the finished NCT00792636 record still lists
NCT00792636 is an interventional study that assigns participants to a tested intervention. The registered 407 participants enrollment target is mid-sized for trials with a published cap, above the 296-participant average among 21 other Migraine Disorders trials with a reported enrollment target (38% higher).
The record links to 1 condition, with Migraine Disorders appearing as the primary indexed condition, and to 3 interventions - of which sumatriptan and naproxen sodium combination tablet is the first listed.
NCT00792636 names 20 study sites across 6 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT00792636 about?
NCT00792636 is a clinical study titled "A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period". The purpose of this study is to test the effect on blood pressure of sumatriptan and naproxen sodium combination tablets, tablets containing only sumatriptan, and tablets containing only naproxen sodium when these drugs are taken to treat migraine headaches that occur during a 6-month period.
What is the current status of trial NCT00792636?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 407 participants. The study started on 2008-11. Estimated completion is 2009-11.
What conditions does trial NCT00792636 study?
This clinical trial studies the following conditions: Migraine Disorders.
What interventions are being tested in trial NCT00792636?
The interventions under investigation include: sumatriptan and naproxen sodium combination tablet (DRUG), sumatriptan tablet (DRUG), naproxen sodium tablet (DRUG).
Who is sponsoring clinical trial NCT00792636?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00792636 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00792636's enrollment target sits among peer trials
407 6th of 21 higher than 16 of 21 other Migraine Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
RECRUITING · Phase 4
-
Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults
COMPLETED · Phase 4
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
-
Mind Body Balance for Pediatric Migraine
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06735534 · 407 participants · NA
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
- NCT07094516 · 407 participants · Phase 2
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
- NCT04835428 · 408 participants · NA
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
- NCT05836324 · 408 participants · Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia